Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of venetoclax + dexamethasone versus pomalidomide + dexamethasone in relapsed or refractory t(11;14)-positive multiple myeloma
MOH_2018-07-30_002483Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Venetoclax + dexamethasone with Pomalidomide + dexamethasone (2 arms). Started Apr 2018; status: completed.
02
Drugs
venetoclaxpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2018-07-30_002483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-30_002483.